Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

March 14, 2024

Study Completion Date

March 14, 2024

Conditions
Peritoneal Metastases
Interventions
DRUG

Allocetra-OTS

Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.

Trial Locations (1)

Unknown

The Chaim Sheba Medical Center, Ramat Gan

Sponsors
All Listed Sponsors
lead

Enlivex Therapeutics RDO Ltd.

INDUSTRY

NCT05431907 - Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis | Biotech Hunter | Biotech Hunter